US-based drug company says COVID-19 treatment could be ready for use by September

A US-based drug company Eli Lilly and Co have said that a medicine specifically designed to treat dely COVID-19 disease will be authorised for use for as early as September 2020. In an exclusive interview with Reuters, company’s chief scientist said on June 10 that if everything proceeds as planned with two antibody rapies alrey in ir testing, COVID-19 drug will be on its way. Just recently, Eli Lilly and Co h anunced starting of Phase 1 study for ir second potential antibody treatment designed to combat disease caused by vel coronavirus which has till w infected over 7.3 million people in world. 

Company’s Chief Scientific Officer Daniel Skovronsky reportedly said in same interview that Eli Lilly And Co has even started preclinical studies for a third antibody treatment to COVID-19 with previous two experimental rapies alrey subjected to human trials. company has developed moclonal antibody drug to combat COVID-19 which has widely been used in treatment of or diseases such as cancer, rheumatoid arthritis. This of biotech medicine is more likely to be beneficial against vel coronavirus as compared to repurposed drugs that are also being tested. Earlier in May, US-based company h revealed that it h started testing for two different antibody treatments with one being developed in partnership with Canian biotech AbCellera and second one being developed with Chinese drugmaker Shanghai Junshi Biosciences.

Re - Foreigner Held With Drugs Worth Rs 50 Lakh In Delhi

Re - COVID-19: Centre May Soon Allow Import Of Treatment Drugs Under Trial In Or Countries

Triple-drug combination against COVID-19

As countries across world are ramping up ir research to find a definite cure and vaccine to coronavirus disease, a new study has found out that a combination of three antiviral drugs along with an immunity booster quickly treats patients of COVID-19 infection. Even though researchers claim that approach requires more testing but it can be a potential treatment for coronavirus patients. Dr Kwok-Yung at Hong Kong University and colleagues reportedly tested combination of HIV drug, remdesvir with ritonavir and lopanivir, general antiviral drug ribavirin and a multiple sclerosis drug beta interferon.

findings of new study came when only authorized treatment for coronavirus disease remains experimental antiviral drug remdesivir. Countries including United States and Japan have alrey approved emergency use of drug over patients who show severe symptoms of COVID-19 infection. However, global infections of vel virus have surpassed four million but supply of HIV drug is limited.

Re - Health Ministry Drafts Rules To Help COVID-19 Patients Access New Drugs

Re - Health Ministry Relaxes rms For Import Of Unapproved Drugs For 'compassionate Use'

(Im Source: Representative/Unsplash)

(With ncy inputs)